Your browser doesn't support javascript.
loading
First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease.
Herrmann, Ken; Schottelius, Margret; Lapa, Constantin; Osl, Theresa; Poschenrieder, Andreas; Hänscheid, Heribert; Lückerath, Katharina; Schreder, Martin; Bluemel, Christina; Knott, Markus; Keller, Ulrich; Schirbel, Andreas; Samnick, Samuel; Lassmann, Michael; Kropf, Saskia; Buck, Andreas K; Einsele, Hermann; Wester, Hans-Juergen; Knop, Stefan.
Afiliación
  • Herrmann K; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California her
  • Schottelius M; Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany.
  • Lapa C; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Osl T; Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany.
  • Poschenrieder A; Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany.
  • Hänscheid H; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Lückerath K; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Schreder M; Department of Internal Medicine II, Division of Hematology and Medical Oncology, Universitätsklinikum Würzburg, Würzburg, Germany.
  • Bluemel C; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Knott M; Department of Internal Medicine II, Division of Hematology and Medical Oncology, Universitätsklinikum Würzburg, Würzburg, Germany.
  • Keller U; Department of Medicine III (Hematology/Oncology), Technische Universität München, Munich, Germany German Cancer Consortium (DKTK) and Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany; and.
  • Schirbel A; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Samnick S; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Lassmann M; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Kropf S; Scintomics GmbH, Fürstenfeldbruck, Germany.
  • Buck AK; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Einsele H; Department of Internal Medicine II, Division of Hematology and Medical Oncology, Universitätsklinikum Würzburg, Würzburg, Germany.
  • Wester HJ; Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany.
  • Knop S; Department of Internal Medicine II, Division of Hematology and Medical Oncology, Universitätsklinikum Würzburg, Würzburg, Germany.
J Nucl Med ; 57(2): 248-51, 2016 Feb.
Article en En | MEDLINE | ID: mdl-26564323
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Radiofármacos / Receptores CXCR4 / Mieloma Múltiple Aspecto: Ethics Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Nucl Med Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Radiofármacos / Receptores CXCR4 / Mieloma Múltiple Aspecto: Ethics Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Nucl Med Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos